EMG-Health | Episode 90
This week, Jonathan hosts Chiara De Biase, Director of Support and Influencing, Prostate Cancer UK, and Amy Rylance, Head of Improving Care, Prostate Cancer UK. They discuss the implications of the coronavirus pandemic on prostate cancer in the UK, as well as current modes of raising awareness, and emerging treatment options in the form of novel hormonal therapies.
Spotify | Apple | Download MP3 (mp3, 43:33 mins)
Access the Prostate Cancer UK website here: www.prostatecanceruk.org
Use this link to complete the risk checker discussed in this episode: https://prostatecanceruk.org/risk-checker
Speaker Bio
Chiara De Biase has degrees from the University of Northampton, Brunel University London, and the University of Westminster. She brings a wealth of experience; both clinically from her time working as a Senior Physiotherapist at Barts and The London NHS Trust, but also in management positions at King’s College Hospital, London, Anthony Nolan and the Candlelighters Trust. Chiara is now Director of Support and Influencing at Prostate Cancer UK.
Amy Rylance is Head of Improving Care at Prostate Cancer UK, aiming to achieve improved care by spreading uptake of evidence-based innovation, education, and growing clinical leadership. She has previously worked for Diabetes UK, as the Head of Healthcare Engagement and Development, and graduated from the University of Leeds. Amy’s work helps to translate research into NHS practice, and she has been granted the Royal Society Rosalind Franklin Award for her work in senior healthcare leadership.
